Biohaven CEO says drug approval is 'monumental' for migraine patients

"This is going to change the paradigm in which migraine is treated," Biohaven Pharmaceutical CEO Vlad Coric said after Nurtec ODT received FDA approval.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.